Hemostemix (CVE:HEM) Shares Down 16.7% – Time to Sell?

Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 16.7% during mid-day trading on Tuesday . The company traded as low as C$0.10 and last traded at C$0.10. Approximately 236,500 shares traded hands during trading, a decline of 15% from the average daily volume of 278,294 shares. The stock had previously closed at C$0.12.

Hemostemix Stock Down 16.7 %

The company’s 50-day moving average is C$0.09 and its 200 day moving average is C$0.07. The company has a market cap of C$8.71 million, a price-to-earnings ratio of -5.00 and a beta of 0.20.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Read More

• Five stocks we like better than Hemostemix
• Comparing and Trading High PE Ratio Stocks
• Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
• What is the S&P/TSX Index?
• How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
• Investing in Construction Stocks
• Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac